2. Signaling Pathways
  3. GPCR/G Protein
  4. P2Y Receptor

P2Y Receptor

P2Y Receptor

Related Products

PDF 0.7 MB

P2Y receptors are a class of G protein-coupled receptors (GPCRs) activated by extracellular nucleotides (ATP, UTP, and UDP). There are eight mammalian P2Y receptor subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14). The P2Y receptors are expressed in various cell types and play important roles in physiology and pathophysiology including inflammatory responses and neuropathic pain.

The P2Y family can be further divided into a subfamily of five P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11Rs (“P2Y1-like”) that stimulate phospholipase C (PLC) through Gq protein and a second subfamily of P2Y12, P2Y13, and P2Y14Rs (“P2Y12-like”) that inhibit adenylate cyclase through Gi protein. Other effector pathways have been documented, such as coupling of the P2Y11R to Gs as well as to Gq in some cells to induce stimulation of cyclic AMP production.

P2Y Receptor Related Products (80):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-110126
    AR-C118925XX
    		Antagonist ≥99.0%
    AR-C118925XX is a selective P2Y2 receptor antagonist. AR-C118925XX inhibits ATP-induced IL-6 production and phosphorylation of p38. AR-C118925XX also inhibits Bleomycin (HY-108345)-induced dermal fibrosis in mice. AR-C118925XX also inhibits ATP-induced tumor growth.
    AR-C118925XX
  • HY-125989
    2-Methylthio-AMP
    		Antagonist 99.30%
    2-Methylthio-AMP (2-MeSAMP) is a selective and direct P2Y12 antagonist. 2-Methylthio-AMP is an inhibitor of ADP-dependent platelet aggregation.
    2-Methylthio-AMP
  • HY-146486
    P2Y2R/GPR17 antagonist 1
    		Inhibitor 98.85%
    P2Y2R/GPR17 antagonist 1 (Compound 14m) is a dual P2Y2R and GPR17 antagonist with IC50 values of 3.17 µM and 1.67 µM against P2Y2R and GPR17, respectively. P2Y2R/GPR17 antagonist 1 shows excellent metabolic stability in human liver microsomes.
    P2Y2R/GPR17 antagonist 1
  • HY-108672
    NF157
    		Antagonist
    NF157 is a highly selective nanomolar P2Y11 antagonist with a pKi of 7.35. The IC50s are 463 nM, 1811 µM, 170 µM for P2Y11 (Ki=44.3 nM), P2Y1 (Ki=187 µM), P2Y2 (Ki=28.9 µM), respectively. NF157, significantly reduces expression of metalloproteinase (MMP)-3, MMP-13, can be used in the treatment of osteoarthritis (OA).
    NF157
  • HY-18775
    N6-(4-Hydroxybenzyl)adenosine
    		Inhibitor 99.96%
    N6-(4-Hydroxybenzyl)adenosine is a inhibitor of platelet aggregation induced in vitro by collagen and their activity range was demonstrated (IC50: 6.
    N6-(4-Hydroxybenzyl)adenosine
  • HY-108658
    MRS2500 tetraammonium
    		Antagonist 99.85%
    MRS2500 tetraammonium is a potent, selective and stable antagonist of the P2Y1 receptor (Ki=0.78 nM for recombinant human P2Y1 receptor). MRS2500 tetraammonium inhibits the ADP-induced aggregation of human platelets with an IC50 value of 0.95 nM. Antithrombotic activity.
    MRS2500 tetraammonium
  • HY-15284A
    Prasugrel hydrochloride
    		Inhibitor 98.90%
    Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
    Prasugrel hydrochloride
  • HY-118284
    Vicagrel
    		Inhibitor 98.86%
    Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
    Vicagrel
  • HY-15876
    Clopidogrel thiolactone
    		Inhibitor ≥98.0%
    Clopidogrel thiolactone is an important intermediate in the metabolism of clopidogrel (HY-15283). Clopidogrel thiolactone has antiplatelet aggregatione effects. Clopidogrel is a P2Y12 receptor inhibitor that exerts antiplatelet effects.
    Clopidogrel thiolactone
  • HY-108662
    PIT
    		Antagonist 98.57%
    PIT (2,2'-Pyridylisatogen tosylate) is a selective and non-competitive antagonist of P2Y1 receptor with an IC50 value of 0.14 μM for human P2Y1 receptor. PIT antagonizes P2Y1 receptor signaling without affecting nucleotide binding. PIT is an irreversible antagonist of responses to ATP at metabotropic purinoceptors (of the P2Y family) in some smooth muscles. PIT can be used for the research of chronic bronchitis and asthma.
    PIT
  • HY-108661A
    NF546 hydrate
    		Agonist
    NF546 (hydrate) is a selective non-nucleotide P2Y11 agonist with a pEC50 of 6.27. NF546 (hydrate) stimulates release of interleukin-8 from human monocyte-derived dendritic cells.
    NF546 hydrate
  • HY-11021
    Elinogrel
    		Antagonist 98.68%
    Elinogrel (PRT060128) is a potent, direct acting, competitive, and reversible platelet P2Y12 antagonist (IC50=20 nM). It is orally and intravenously available and has potent antiplatelet effects.
    Elinogrel
  • HY-101308A
    MRS2179 tetrasodium hydrate
    		Antagonist ≥99.0%
    MRS2179 tetrasodium hydrate is a competitive P2Y1 receptor antagonist, with a Kb of 102 nM and a pA2 of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium hydrate is selective for P2Y1 over P2X1 (IC50=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors. MRS2179 tetrasodium hydrate inhibits platelet aggregation.
    MRS2179 tetrasodium hydrate
  • HY-15799
    AZD1283
    		Antagonist 99.27%
    AZD1283 is a potent P2Y12 receptor antagonist with a binding IC50 of 11 nM and a GTPγS IC50 of 25 nM. AZD1283 has excellent antiplatelet aggregation potency. AZD1283 can be used to research thromboembolic disorders.
    AZD1283
  • HY-108656
    MRS2365
    		Agonist
    MRS2365 is a potent and selective P2Y1 receptor (EC50=0.4 nM) /[35S]GTPγS binding/β-arrestin 2 recruitment agonist with an EC50 of 0.4 nM. MRS2365 relieves mechanical allodynia and increases mechanical sensitivity. MRS2365 shows little agonist or antagonist activity at the P2Y12 or P2Y13 receptors.
    MRS2365
  • HY-108656A
    MRS2365 trisodium
    		Agonist ≥99.0%
    MRS2365 trisodium is a potent and selective P2Y1 receptor (EC50=0.4 nM)/[35S]GTPγS binding/β-arrestin 2 recruitment agonist. MRS2365 trisodium relieves mechanical allodynia and increases mechanical sensitivity.
    MRS2365 trisodium
  • HY-108648
    2-Methylthioadenosine diphosphate trisodium
    		Agonist
    2-Methylthioadenosine diphosphate trisodium is a potent purinergic P2Y receptors agonist, with EC50s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-Methylthioadenosine diphosphate trisodium has pEC50s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-Methylthioadenosine diphosphate trisodium induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1.
    2-Methylthioadenosine diphosphate trisodium
  • HY-108657A
    MRS2279 diammonium
    		Antagonist ≥98.0%
    MRS2279 diammonium is a selective and high affinity P2Y1 receptor antagonist, with a Ki value of 2.5 nM and an IC50 value of 51.6 nM. MRS2279 diammonium competitively inhibits ADP-promoted platelet aggregation with an pKb value of 8.05.
    MRS2279 diammonium
  • HY-15284S1
    Prasugrel-d3
    		Inhibitor 98.58%
    Prasugrel-d3 is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].
    Prasugrel-d<sub>3</sub>
  • HY-108649A
    MRS2768 tetrasodium salt
    		Agonist 98.70%
    MRS2768 tetrasodium salt is a moderately potent and selective P2Y2 receptor agonist. MRS2768 tetrasodium salt has a protective effect on cardiomyocytes from ischemic damage in vivo and in vitro.
    MRS2768 tetrasodium salt